Download Files:
TT-232
$80 – $550
Products Details
Product Description
– TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].
Web ID
– HY-105172
Storage Temperature
– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C45H58N10O9S2
References
Р[1]Szende B, et al. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs. 2003 Sep;14(8):585-8. |[2]K̩ri G, et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12513-8. |[3]Tejeda M, et al. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25(1A):325-30. |[4]Pint̩r E, et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):142-50.
CAS Number
– 147159-51-1
Molecular Weight
– 947.13
Compound Purity
– 98.96
SMILES
– O=C(N[C@H](C(N[C@@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC1)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC(C=C3)=CC=C3O)=O)CC4=CNC5=CC=CC=C45
Clinical Information
– Phase 2
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Somatostatin Receptor
Isoform
– SSTR1;SSTR4
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Peptides
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
Related Products
1000 in stock
